Literature DB >> 15222033

Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs.

Tong-Dong Shi1, Yu-Zhang Wu, Zheng-Cai Jia, Li-Yun Zou, Wei Zhou.   

Abstract

AIM: To explore how to improve the immunogenicity of HBcAg CTL epitope based polypeptides and to trigger an HBV-specific HLA I-restricted CD8+ T cell response in vitro.
METHODS: A new panel of mimetic therapeutic peptides based on the immunodominant B cell epitope of HBV PreS2 18-24 region, the CTL epitope of HBcAg18-27 and the universal T helper epitope of tetanus toxoid (TT) 830-843 was designed using computerized molecular design method and synthesized by Merrifield's solid-phase peptide synthesis. Their immunological properties of stimulating activation and proliferation of lymphocytes, of inducing T( H1) polarization, CD8+ T cell magnification and HBV-specific CD8+ CTL mediated cytotoxicity were investigated in vitro using HLA-A2+ human peripheral blood mononuclear cells (PBMCs) from healthy donors and chronic hepatitis B patients.
RESULTS: Results demonstrated that the therapeutic polypeptides based on immunodominant HBcAg18-27 CTL, PreS2 B- and universal T(H) epitopes could stimulate the activation and proliferation of lymphocytes, induce specifically and effectively CD8+ T cell expansion and vigorous HBV-specific CTL-mediated cytotoxicity in human PBMCs.
CONCLUSION: It indicated that the introduction of immunodominant T helper plus B-epitopes with short and flexible linkers could dramatically improve the immunogenicity of short CTL epitopes in vitro.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15222033      PMCID: PMC4572227          DOI: 10.3748/wjg.v10.i13.1902

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  35 in total

1.  Viral immunology: challenges associated with the progression from bench to clinic.

Authors:  Marcia A Blackman; Barry T Rouse; Frank V Chisari; David L Woodland
Journal:  Trends Immunol       Date:  2002-12       Impact factor: 16.687

Review 2.  Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope-specific B-, T-helper and T-killer cell response.

Authors:  K H Wiesmüller; W G Bessler; G Jung
Journal:  Int J Pept Protein Res       Date:  1992 Sep-Oct

3.  Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules.

Authors:  B D Livingston; C Crimi; J Fikes; R W Chesnut; J Sidney; A Sette
Journal:  Hum Immunol       Date:  1999-11       Impact factor: 2.850

Review 4.  Towards immunotherapy for chronic hepatitis B virus infections.

Authors:  M-L Michel
Journal:  Vaccine       Date:  2002-12-19       Impact factor: 3.641

Review 5.  Peptide vaccines against hepatitis B virus: from animal model to human studies.

Authors:  O B Engler; W J Dai; A Sette; I P Hunziker; J Reichen; W J Pichler; A Cerny
Journal:  Mol Immunol       Date:  2001-12       Impact factor: 4.407

Review 6.  NK-cell activity in immunotoxicity drug evaluation.

Authors:  Karin Cederbrant; Maritha Marcusson-Ståhl; Fabienne Condevaux; Jacques Descotes
Journal:  Toxicology       Date:  2003-04-01       Impact factor: 4.221

7.  Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I-restricted cytotoxic T cells.

Authors:  Detlef Stober; Zlatko Trobonjaca; Jörg Reimann; Reinhold Schirmbeck
Journal:  Eur J Immunol       Date:  2002-04       Impact factor: 5.532

8.  Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans.

Authors:  B D Livingston; J Alexander; C Crimi; C Oseroff; E Celis; K Daly; L G Guidotti; F V Chisari; J Fikes; R W Chesnut; A Sette
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

9.  Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections.

Authors:  Kazuhiro Kakimi; Masanori Isogawa; JoSan Chung; Alessandro Sette; Francis V Chisari
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Transcriptional and posttranscriptional control of hepatitis B virus gene expression.

Authors:  Susan L Uprichard; Stefan F Wieland; Alana Althage; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

View more
  9 in total

Review 1.  Research progress of therapeutic vaccines for treating chronic hepatitis B.

Authors:  Jianqiang Li; Mengru Bao; Jun Ge; Sulin Ren; Tong Zhou; Fengchun Qi; Xiuying Pu; Jia Dou
Journal:  Hum Vaccin Immunother       Date:  2017-01-24       Impact factor: 3.452

2.  Immune-induced evolutionary selection focused on a single reading frame in overlapping hepatitis B virus proteins.

Authors:  Yaakov Maman; Antoine Blancher; Jennifer Benichou; Adi Yablonka; Sol Efroni; Yoram Louzoun
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

3.  Ethanol attenuates presentation of cytotoxic T-lymphocyte epitopes on hepatocytes of HBV-infected humanized mice.

Authors:  Murali Ganesan; Weimin Wang; Saumi Mathews; Edward Makarov; Moses New-Aaron; Raghubendra Singh Dagur; Antje Malo; Ulrike Protzer; Kusum K Kharbanda; Carol A Casey; Larisa Y Poluektova; Natalia A Osna
Journal:  Alcohol Clin Exp Res       Date:  2021-11-23       Impact factor: 3.455

4.  Acetaldehyde suppresses the display of HBV-MHC class I complexes on HBV-expressing hepatocytes.

Authors:  Murali Ganesan; Vjaceslav M Krutik; Edward Makarov; Saumi Mathews; Kusum K Kharbanda; Larisa Y Poluektova; Carol A Casey; Natalia A Osna
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-05-29       Impact factor: 4.052

5.  Intensity of HLA-A2 Expression Significantly Decreased in Occult Hepatitis B Infection.

Authors:  Azam Askari; Gholam Hossein Hassanshahi; Seyed Razi Ghalebi; Abdollah Jafarzadeh; Maryam Mohit; Masomeh Hajghani; Mohammad Kazemi Arababadi
Journal:  Jundishapur J Microbiol       Date:  2014-06-01       Impact factor: 0.747

6.  Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy.

Authors:  Fu-Qiang Yang; Gui-Rong Rao; Gui-Qiang Wang; Yue-Qi Li; Yao Xie; Zhan-Qing Zhang; Cun-Liang Deng; Qing Mao; Jun Li; Wei Zhao; Mao-Rong Wang; Tao Han; Shi-Jun Chen; Chen Pan; De-Ming Tan; Jia Shang; Ming-Xiang Zhang; Yue-Xin Zhang; Ji-Ming Yang; Guang-Ming Chen
Journal:  World J Gastroenterol       Date:  2017-01-14       Impact factor: 5.742

7.  Identification of CTL Epitopes on Efflux Pumps of the ATP-Binding Cassette and the Major Facilitator Superfamily of Mycobacterium tuberculosis.

Authors:  Yan Lin; Yu Dong; Yanfeng Gao; Ranran Shi; Yubing Li; Xiuman Zhou; Wenwen Liu; Guodong Li; Yuanming Qi; Yahong Wu
Journal:  J Immunol Res       Date:  2021-01-05       Impact factor: 4.818

8.  Immunogenicity of twenty peptides representing epitopes of the hepatitis B core and surface antigens by IFN-γ response in chronic and resolved HBV.

Authors:  Nanna-Sophie Brinck-Jensen; Thomas Vorup-Jensen; Peter Derek Christian Leutscher; Christian Erikstrup; Eskild Petersen
Journal:  BMC Immunol       Date:  2015-11-02       Impact factor: 3.615

9.  In Silico Prediction of Human Leukocytes Antigen (HLA) Class II Binding Hepatitis B Virus (HBV) Peptides in Botswana.

Authors:  Wonderful Tatenda Choga; Motswedi Anderson; Edward Zumbika; Bonolo B Phinius; Tshepiso Mbangiwa; Lynnette N Bhebhe; Kabo Baruti; Peter Opiyo Kimathi; Kaelo K Seatla; Rosemary M Musonda; Trevor Graham Bell; Sikhulile Moyo; Jason T Blackard; Simani Gaseitsiwe
Journal:  Viruses       Date:  2020-07-06       Impact factor: 5.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.